Additionally decreased FOXF2 mRNA expression was associated with poor prognosis in Stage I NSCLC patients, and it could predict poor prognosis for patients with Stage I NSCLC independently. The gene discussed is FOXF2; the disease is non-small cell lung carcinoma.